BCIDP - ROUND 2 EXAM QUESTIONS WITH 100% CORRECT ANSWERS LATEST VERSION 2025/2026.

BCIDP - ROUND 2 EXAM QUESTIONS
WITH 100% CORRECT ANSWERS
LATEST VERSION 2025/2026.




What prophylaxis is recommended for HIV patients to prevent opportunistic infections if
CD4<50? - ANS PJP, toxoplasmosis, and MAC



what opportunistic infections are HIV pts at risk for when CD4<200? - ANS oropharyngeal
candidiasis and PJP



what opportunistic infections are HIV pts at risk for when CD4<100? - ANS toxoplasmosis
encephalitis and cryptococcal meningitis



what opportunistic infections are HIV pts at risk for when CD4<50? - ANS MAC and CMV



treatment options for hepC non-cirrhotic - ANS gelcaprevir/pibrentasvir OR

sofosbuvir/velpatasvir



treatment options for hepC compensated cirrhosis (Child Pugh B) -
ANS gelcaprevir/pibrentasvir (all genotypes) OR

sofosbuvir/velpatasvir (all genotypes except 3)


1 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.

, treatment options for hepC decompensated cirrhosis (Child Pugh C) -
ANS ledispavir/sofosbuvir/ribavirin (all genotypes except 2 and 3)

sofosbuvir/velpatasvir/ribivirin (all genotypes)



the NS5A class of hepC drugs (-asvir) have drug interactions with which common drug class -
ANS PPIs



-cannot use velpatasvir

-can use ledipasvir up to 20mg of omeprazole

-can use elbasvir



side effects of linezolid - ANS bone marrow suppression

neuropathies

serotonin syndrome

lactic acidosis

hepatotoxicity



side effects of telavancin - ANS nephrotoxicity

NIOSH drug (adverse reproductive effects)

infusion related reactions

QT prolongation



side effects of ceftaroline - ANS hematologic (anemia, leukopenia/neutropenia)

rash

GI


2 @COPYRIGHT 2025/2026 ALLRIGHTS RESERVED.